XSHE
002773
Market cap3.86bUSD
Jul 11, Last price
30.50CNY
1D
4.85%
1Q
16.46%
Jan 2017
-30.18%
IPO
175.73%
Name
Chengdu Kanghong Pharmaceutical Group Co Ltd
Chart & Performance
Profile
Chengdu Kanghong Pharmaceuticals Group Co., Ltd engages in the research, development, production, and sale of biological products, Chinese medicines, and chemical drugs in China. It offers ophthalmic systems, central nervous systems, digestive systems, and other system drugs. The company was founded in 1996 and is headquartered in Chengdu, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 3,957,460 16.77% | 3,389,028 -6.00% | |||||||
Cost of revenue | 1,870,267 | 2,231,510 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 2,087,193 | 1,157,518 | |||||||
NOPBT Margin | 52.74% | 34.15% | |||||||
Operating Taxes | 202,793 | 164,485 | |||||||
Tax Rate | 9.72% | 14.21% | |||||||
NOPAT | 1,884,400 | 993,032 | |||||||
Net income | 1,044,766 16.52% | 896,670 112.94% | |||||||
Dividends | (137,920) | (91,946) | |||||||
Dividend yield | 0.82% | 0.64% | |||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 1,598 | ||||||||
Long-term debt | 2,959 | 6,536 | |||||||
Deferred revenue | 17,308 | 23,273 | |||||||
Other long-term liabilities | 36,600 | 88,510 | |||||||
Net debt | (4,742,377) | (3,677,235) | |||||||
Cash flow | |||||||||
Cash from operating activities | 1,218,411 | 925,153 | |||||||
CAPEX | (138,874) | ||||||||
Cash from investing activities | 6,616 | ||||||||
Cash from financing activities | (130,498) | ||||||||
FCF | 2,022,057 | 541,217 | |||||||
Balance | |||||||||
Cash | 4,702,143 | 3,685,369 | |||||||
Long term investments | 43,194 | ||||||||
Excess cash | 4,547,463 | 3,515,917 | |||||||
Stockholders' equity | 5,308,346 | 4,930,463 | |||||||
Invested Capital | 3,319,841 | 3,466,545 | |||||||
ROIC | 55.53% | 29.38% | |||||||
ROCE | 26.50% | 16.57% | |||||||
EV | |||||||||
Common stock shares outstanding | 916,461 | 919,464 | |||||||
Price | 18.44 17.53% | 15.69 -22.90% | |||||||
Market cap | 16,899,544 17.14% | 14,426,389 -22.90% | |||||||
EV | 12,165,055 | 10,754,226 | |||||||
EBITDA | 2,312,896 | 1,315,790 | |||||||
EV/EBITDA | 5.26 | 8.17 | |||||||
Interest | 151 | ||||||||
Interest/NOPBT | 0.01% |